- Details
- Alicia Morgans speaks with Mary-Ellen Taplin about strategies for managing metastatic hormone-sensitive prostate cancer (mHSPC) patients who do not achieve optimal PSA declines. Dr. Taplin emphasizes that an unfavorable PSA decline is not synonymous with progression and highlights the prognostic value of achieving a PSA nadir below 0.2. She discusses data from various trials, such as SWOG 9346, CH...
|
- Details
- Alicia Morgans interviews Sandy Srinivas about her presentation on treating the primary tumor in synchronous high-volume metastatic hormone-sensitive prostate cancer. Dr. Srinivas reviews key trials such as HORRAD and STAMPEDE, which indicate that radiating the primary tumor may benefit low-volume patients but not those with high-volume disease. She highlights the PEACE-1 trial, which found no sur...
|
- Details
- Alicia Morgans speaks with Matthew Smith about prognostic and predictive factors in treating metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Smith explains the importance of clinical, imaging, and molecular factors in patient selection for treatment intensification. He highlights that factors like disease volume, manner of presentation, and specific genomic alterations (e.g., PTEN, P53)...
|
- Details
- Alicia Morgans interviews Ian Davis to discuss the challenges of sequencing treatments for patients with metastatic hormone-sensitive prostate cancer (mHSPC) that have progressed to metastatic castrate-resistant disease (mCRPC). Dr. Davis emphasizes that there is no ideal sequence of treatments but identifies several less-than-ideal approaches. He highlights the importance of achieving maximum ben...
|
- Details
- Maria De Santis discusses managing frail patients with metastatic hormone-sensitive prostate cancer. Dr. De Santis explains the importance of defining frailty, which involves five key factors: unintended weight loss, weakness, low physical activity, difficulty lifting objects, and mobility issues. She highlights the necessity of evaluating frailty using tools like the G8 screening and emphasizes t...
|
- Details
- Michael Morris discusses optimal imaging standards for metastatic hormone-sensitive prostate cancer. He explains that conventional imaging methods like PSA tracking are insufficient for monitoring disease progression in the era of advanced androgen receptor signaling inhibitors (ARSIs). Dr. Morris emphasizes the need for regular imaging, recommending scans every six to twelve months to detect radi...
|
- Details
- Zach Klaassen discusses the EvoPAR-Prostate 01 trial with Neeraj Agarwal. The trial examines a new PARP inhibitor combined with ARPI in metastatic hormone-sensitive prostate cancer, both in biomarker-positive and -negative populations. Dr. Agarwal explains the rationale based on preclinical data and previous trials like PROpel and TALAPRO-2, showing efficacy in HRR mutation-positive patients and p...
|
- Details
- Alicia Morgans speaks with Bertrand Tombal about his presentation at EAU 2024, focusing on the European subset of the ARASENS trial. Professor Tombal discusses the importance of the data from this trial, which assessed the efficacy of adding darolutamide to standard treatment for metastatic hormone-naive prostate cancer. The trial confirmed that this combination significantly reduced mortality ris...
|
- Details
- Alicia Morgans and Alberto Bossi discuss the integration of local prostate treatment in metastatic hormone-sensitive prostate cancer, focusing on findings from the PEACE-1 trial and related studies. Professor Bossi highlights the challenge in identifying patients who could benefit most from local radiotherapy, especially given the evolution in imaging technologies like PSMA PET, which may redefine...
|
- Details
- Zach Klaassen and Kelvin Moses discuss the continuum of care for metastatic hormone-sensitive prostate cancer, focusing on triplet therapy. Dr. Moses highlights the ideal patient profile for this treatment, emphasizing collaboration between urology and medical oncology. They stress the manageable nature of chemotherapy and its finite duration. The conversation extends to disparities in prostate ca...
|
